Yang-Xin Fu, M.D., Ph.D., Professor of Pathology, studies immunotherapy and immunopathology in cancer and infectious diseases. His current research interests include investigating and understanding the mechanisms underlying IR-induced extrinsic resistance as well as testing newly developed personalized immunotherapies to overcome these resistance mechanisms for improved and long-lasting tumor control.

After completing his clinical training in pathology at Washington University in St. Louis (1998), Dr. Fu organized his own team to focus his research on understanding the role of the lymphoid microenvironment in cellular and humoral immune responses using various TNF superfamily members such as the LIGHT/lymphotoxin pathway.

His team has published more than 50 papers relating to the mechanistic understanding of autoimmunity and immunity against pathogens and tumor in top journals (e.g., Science, Nature, Nature Immunology, Nature Medicine, Cancer Cell, Immunity, Journal of Experimental Medicine, and Journal of Clinical Investigation). He has directed clinical, translational, and preclinical studies in immunology––tumor immunology in particular––for more than 15 years. Recently, his team has been developing novel immunotherapeutic molecules, antibodies and armed antibodies by protein engineering. They have established mouse tumor models expressing various oncogenic receptors to mimic clinical tumors and have made significant progress in understanding how traditional cancer therapies both rely on and impact the immune system.


Medical School
Shanghai Medical University (1983), Medicine
Graduate School
University of Miami (1990), Immunology

Research Interest

  • IR-mediated immunity and tumor regression
  • Lymphotoxin biology and gut Immunity
  • Next generation antibody-based molecules
  • Tumor immunology


Featured Publications LegendFeatured Publications

Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse.
Pu Y, Xu M, Liang Y, Yang K, Guo Y, Yang X, Fu YX Sci Transl Med 2016 Apr 8 333 333ra47
CD47 blockade triggers T cell-mediated destruction of immunogenic tumors.
Liu X, Pu Y, Cron K, Deng L, Kline J, Frazier WA, Xu H, Peng H, Fu YX, Xu MM Nat. Med. 2015 Oct 21 10 1209-15
STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.
Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, Li XD, Mauceri H, Beckett M, Darga T, Huang X, Gajewski TF, Chen ZJ, Fu YX, Weichselbaum RR Immunity 2014 Nov 41 5 843-52
Innate lymphoid cells facilitate NK cell development through a lymphotoxin-mediated stromal microenvironment.
Kim TJ, Upadhyay V, Kumar V, Lee KM, Fu YX J. Exp. Med. 2014 Jun 211 7 1421-31
LIGHT delivery to tumors by mesenchymal stem cells mobilizes an effective antitumor immune response.
Zou W, Zheng H, He TC, Chang J, Fu YX, Fan W Cancer Res. 2012 Jun 72 12 2980-9